
Biocon Biologics India, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon (BSE: 532523) and Mylan (Nasdaq: MYL) yesterday announced the US launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
News of the launch sent Biocon’s shares up 4.2% to 375., while Mylan stock edged up less than 1% to $16.38.nch saw Biocon’s shares close up 4.2% at 375.00 rupees
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze